Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Effect of Hepatic Disease on Pharmacokinetics: Pathophysiologic Assessment and Liver Function Test01:22

Effect of Hepatic Disease on Pharmacokinetics: Pathophysiologic Assessment and Liver Function Test

79
In clinical practice, the direct measurement of hepatic blood flow to evaluate liver function presents significant challenges due to the intricate and specialized nature of the necessary techniques. Consequently, healthcare professionals often rely on empirical estimates derived from thorough patient examinations and liver function tests to gauge liver health. Among the tools at their disposal, the Child–Pugh and MELD scoring systems stand out for their ability to categorize and assess...
79
Effect of Hepatic Disease on Pharmacokinetics: Drug Dosing and Hepatic Blood Flow01:26

Effect of Hepatic Disease on Pharmacokinetics: Drug Dosing and Hepatic Blood Flow

104
Chronic liver disease significantly impacts drug metabolism due to alterations in hepatic blood flow and enzyme accessibility. This disruption affects the body's pharmacokinetics—the movement and processing of drugs within the system. Key enzymes crucial for metabolizing medications become less accessible, changing how drugs are processed and utilized. Furthermore, liver disease influences the synthesis of plasma proteins, such as albumin and globulins, which play critical roles in drug...
104
Drug Dosing in Renal Diseases: Estimation of Glomerular Filtration Rate Based on Serum Creatinine Concentration01:28

Drug Dosing in Renal Diseases: Estimation of Glomerular Filtration Rate Based on Serum Creatinine Concentration

79
Glomerular filtration rate (GFR) can be estimated from serum creatinine using the modification of diet in renal disease (MDRD) formula or the chronic kidney disease–epidemiology collaboration (CKD–EPI) equation. Both methods are widely used in clinical practice to assess kidney function and guide treatment decisions.The MDRD equation does not require weight or height measurements and is normalized to the body surface area of 1.73 m², considered the average adult surface area.
79
Ultrasound II: Endoscopic Ultrasound and FibroScan01:25

Ultrasound II: Endoscopic Ultrasound and FibroScan

304
Endoscopic Ultrasound (EUS) and FibroScan are valuable diagnostic tools in gastroenterology and hepatology, each with specific applications and techniques.
Endoscopic Ultrasound (EUS):
304

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Delisting From Clinical Improvement in Liver Cirrhosis: A Machine Learning Decision Tree Analysis.

Transplantation·2026
Same author

Hepatic Venous Pressure Gradient, Noninvasive Tests, and Prognosis Across the Subtypes of Advanced Steatotic Liver Disease.

Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association·2026
Same author

Diagnostic innovation and models of care to improve fibrosis detection and risk stratification in steatotic liver disease.

The Lancet regional health. Europe·2026
Same author

Noninvasive diagnosis of clinically significant portal hypertension: current evidence and future directions.

Expert review of gastroenterology & hepatology·2026
Same author

Noninvasive Testing for Metabolic Dysfunction-Associated Steatohepatitis (MASH) and Fibrosis.

Clinics in liver disease·2026
Same author

Diagnosing and defining MASLD in people living with chronic hepatitis B.

Communications medicine·2026

Related Experiment Video

Updated: Nov 19, 2025

Novel In Vivo Micro-Computed Tomography Imaging Techniques for Assessing the Progression of Non-Alcoholic Fatty Liver Disease
08:41

Novel In Vivo Micro-Computed Tomography Imaging Techniques for Assessing the Progression of Non-Alcoholic Fatty Liver Disease

Published on: March 24, 2023

1.5K

NAFLD: Diagnostic Algorithms for Regulating Patient Fluxes.

Giada Pallini1, Emmanuel A Tsochatzis1

  • 1UCL Institute for Liver and Digestive Health, Royal Free Hospital and UCL, London, United Kingdom.

Current Pharmaceutical Design
|January 28, 2021
PubMed
Summary

Non-invasive testing for Non-alcoholic fatty liver disease (NAFLD) fibrosis can improve diagnosis and care. An integrated approach between primary and secondary care is key to managing referrals and detecting liver disease early.

Keywords:
ELFFIB-4Steatohepatitiscirrhosis.non-invasive fibrosis testsprimary care

More Related Videos

Application of Ultrasound and Shear Wave Elastography Imaging in a Rat Model of NAFLD/NASH
07:13

Application of Ultrasound and Shear Wave Elastography Imaging in a Rat Model of NAFLD/NASH

Published on: April 20, 2021

4.3K
A Computer-Based Platform for Aiding Clinicians in Eating Disorder Analysis and Diagnosis
04:19

A Computer-Based Platform for Aiding Clinicians in Eating Disorder Analysis and Diagnosis

Published on: May 10, 2022

4.2K

Related Experiment Videos

Last Updated: Nov 19, 2025

Novel In Vivo Micro-Computed Tomography Imaging Techniques for Assessing the Progression of Non-Alcoholic Fatty Liver Disease
08:41

Novel In Vivo Micro-Computed Tomography Imaging Techniques for Assessing the Progression of Non-Alcoholic Fatty Liver Disease

Published on: March 24, 2023

1.5K
Application of Ultrasound and Shear Wave Elastography Imaging in a Rat Model of NAFLD/NASH
07:13

Application of Ultrasound and Shear Wave Elastography Imaging in a Rat Model of NAFLD/NASH

Published on: April 20, 2021

4.3K
A Computer-Based Platform for Aiding Clinicians in Eating Disorder Analysis and Diagnosis
04:19

A Computer-Based Platform for Aiding Clinicians in Eating Disorder Analysis and Diagnosis

Published on: May 10, 2022

4.2K

Area of Science:

  • Hepatology
  • Gastroenterology
  • Public Health

Background:

  • Non-alcoholic fatty liver disease (NAFLD) affects over 25% globally, driven by obesity and metabolic syndrome.
  • NAFLD is the leading cause of chronic liver disease in industrialized nations.
  • While often benign, NAFLD can progress to advanced fibrosis, cirrhosis, and hepatocellular carcinoma (HCC) in 20% of cases.

Purpose of the Study:

  • To review non-invasive fibrosis testing strategies for NAFLD patients.
  • To enhance diagnostic efficiency and patient care.
  • To optimize referral pathways between primary and secondary care.

Main Methods:

  • Review of current non-invasive fibrosis testing modalities for NAFLD.
  • Analysis of integrated management plans incorporating primary and secondary care.
  • Evaluation of algorithmic approaches for risk stratification.

Main Results:

  • Non-invasive testing can effectively stratify NAFLD fibrosis risk.
  • Integrated care models improve diagnostic accuracy and efficiency.
  • Defined algorithms reduce unnecessary specialist referrals.

Conclusions:

  • Implementing non-invasive fibrosis testing in a structured care pathway is crucial for early NAFLD fibrosis detection.
  • An integrated primary and secondary care approach with defined algorithms is essential for effective NAFLD management.
  • Optimizing diagnostic strategies improves patient outcomes and healthcare resource utilization.